Authors

Latest:

Whole-Blood, 6-Gene Prognostic Signature May Help Personalize Prostate Cancer Treatment

Drs William Oh and Yixuan Gong discuss their research involving a whole-blood, 6-gene prognostic signature that has the potential to help personalize prostate cancer treatment.

By Yair Benita, PhD

Latest:

Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?

Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.

Byoung Chul Cho, MD, PhD, Yonsei Cancer Center at Yonsei University College of Medicine

Byrne Lee, MD

Latest:

Dr. Lee on Data Regarding HIPEC in mCRC

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate clinical professor of surgical oncology, Department of Surgery, and surgical oncologist, City of Hope, discusses data regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with metastatic colorectal cancer (mCRC).

C. Daniel Mullins, PhD

Latest:

Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer

Studies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer

C. E. (Gene) Reeder, RPh, PhD

Latest:

NOW Initiative: Payer & Provider Collaborations in Oncology Benefits Management

Payers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.

C. Kent Osborne, MD

Latest:

Dr. Osborne on Evaluating HER2 Positivity in Breast Cancer

C. Kent Osborne, MD, discusses the important take home message for physicians treating patients with HER2-positive breast cancer. Osborne says the role of HER2-positivity is complicated.

C Leora Horn, MD, MSc, Vanderbilt-Ingram Cancer Center

C. Ola Landgren, MD, Memorial Sloan Kettering Cancer Center

C. Ola Landgren, MD, PhD

C. Ola Landgren, MD, PhD, is a professor of medicine, chief of the Division of Myeloma, Department of Medicine at the University of Miami, Miller School of Medicine; director of the Sylvester Myeloma Institute; co-leader of the Translational and Clinical Oncology Program and Paul J. DiMare Endowed Chair in immunotherapy at the Sylvester Comprehensive Cancer Center

Latest:

Dr Landgren on the Rationale for Assessing Daratumumab Plus KRd in Newly Diagnosed Myeloma

C. Ola Landgren, MD, PhD, discusses the use of MRD as an early end point in a study evaluating daratumumab plus KRd in newly diagnosed multiple myeloma.

C. Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center

C. Parker Gibbs

Latest:

Dr. Gibbs on Testing for p16 and p21 in Osteosarcoma

C. Parker Gibbs Jr, MD, discusses how to test for p16 and p21 in patients with osteosarcoma.

C. Parker Gibbs Jr, MD

Latest:

Dr. Gibbs on the Lack of Treatment Options in Sarcoma

C. Parker Gibbs Jr, MD, discusses the lack of treatment options for patients with soft tissue and bone sarcomas.

Caio Max S. Rocha Lima, MD, Gibbs Cancer Center

Caio Rocha Lima, MD, Gibbs Cancer Center

Caitlin Costello, MD

Latest:

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

Caitlin F. Bell

Latest:

Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast Cancer

Growing attempts to develop biomarkers to guide therapy within triple-negative breast cancer may lead to more effective regimens or to novel therapeutic targets.

Caitlin May, MD

Latest:

Dr. May on Olaratumab Activity in Pediatric Bone and Soft Tissue Sarcoma

Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

Caitlin May, PhD

Latest:

Preclinical Activity With Olaratumab in Sarcoma

Caitlin May, PhD, postdoctoral research scientist at Eli Lilly and Company, discusses preclinical activity with olaratumab (Lynparza) in pediatric sarcoma models.

Camille C. Gunderson, MD

Latest:

Dr. Gunderson on the Use of PARP Inhibitors in All-Comers With Ovarian Cancer

Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.